Safety and immunogenicity of a 15-valent pneumococcal conjugate vaccine in Japanese healthy infants: A Phase I study (V114-028)

Yasunori Ishihara, Haruo Kuroki, Hidenobu Hidaka, Kazuyuki Iwai, Keiko Wan, Masayoshi Shirakawa, Miyuki Sawata, Yasunori Ishihara, Haruo Kuroki, Hidenobu Hidaka, Kazuyuki Iwai, Keiko Wan, Masayoshi Shirakawa, Miyuki Sawata

Abstract

This Phase I study evaluated the safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine (PCV), via subcutaneous (SC) or intramuscular (IM) administration, in healthy Japanese infants 3 months of age. A total of 133 participants were randomized to receive four doses (3 + 1 regimen) of V114-SC (n = 44), V114-IM (n = 45), or 13-valent PCV (PCV13)-SC (n = 44) at 3, 4, 5, and 12-15 months of age. Diphtheria, tetanus, and pertussis-inactivated poliovirus (DTaP-IPV) vaccine was administered concomitantly at all vaccination visits. The primary objective was to assess the safety and tolerability of V114-SC and V114-IM. Secondary objectives were to assess the immunogenicity of PCV and DTaP-IPV at 1-month post-dose 3 (PD3). On days 1-14 following each vaccination, the proportions of participants with systemic adverse events (AEs) were comparable across interventions, whereas injection-site AEs were higher with V114-SC (100.0%) and PCV13-SC (100.0%) than with V114-IM (88.9%). Most AEs were mild or moderate in severity and no vaccine-related serious AEs or deaths were reported. Serotype-specific immunoglobulin G (IgG) response rates at 1-month PD3 were comparable across groups for most shared serotypes between V114 and PCV13. For additional V114 serotypes 22F and 33F, IgG response rates were higher with V114-SC and V114-IM than with PCV13-SC. DTaP-IPV antibody response rates at 1-month PD3 for V114-SC and V114-IM were comparable with PCV13-SC. Findings suggest that vaccination with V114-SC or V114-IM in healthy Japanese infants is generally well tolerated and immunogenic.

Keywords: Clinical trial; DTaP–IPV; Japan; PCV13; PCV15; child; infant; pneumococcal infections; pneumococcal vaccines.

Conflict of interest statement

H.K. has received honoraria for lectures from MSD K.K. K.W., M. Shirakawa and M. Sawata are employees of MSD K.K., Tokyo, Japan and may own stock and/or stock options in Merck & Co., Inc., Rahway, NJ, USA. Y.I., H.H., and K.I. have no conflicts of interest to report.

References

    1. Tan TQ. Pediatric invasive pneumococcal disease in the United States in the era of pneumococcal conjugate vaccines. Clin Microbiol Rev. 2012;25:409–8. doi:10.1128/CMR.00018-12.
    1. Wahl B, O’brien KL, Greenbaum A, Majumder A, Liu L, Chu Y, Luksic I, Nair H, McAllister DA, Campbell H, et al. Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000–15. Lancet Glob Health. 2018;6:e744–57. doi:10.1016/S2214-109X(18)30247-X.
    1. Balsells E, Guillot L, Nair H, Kyaw MH.. Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: a systematic review and meta-analysis. PLoS One. 2017;12:e0177113. doi:10.1371/journal.pone.0177113.
    1. Cleary DW, Jones J, Gladstone RA, Osman KL, Devine VT, Jefferies JM, Bentley SD, Faust SN, Clarke SC. Changes in serotype prevalence of Streptococcus pneumoniae in Southampton, UK between 2006 and 2018. Sci Rep. 2022;12:13332. doi:10.1038/s41598-022-17600-6.
    1. Takeuchi N, Naito S, Ohkusu M, Abe K, Shizuno K, Takahashi A, Omata Y, Nakazawa T, Takeshita K, Hishiki H, et al. Epidemiology of hospitalised paediatric community-acquired pneumonia and bacterial pneumonia following the introduction of 13-valent pneumococcal conjugate vaccine in the national immunisation programme in Japan. Epidemiol Infect. 2020;148:1–11. doi:10.1017/S0950268820000813.
    1. Food and Drug Administration . PREVNAR 13 (Pneumococcal 13-valent conjugate vaccine [Diphtheria CRM197 Protein]) prescribing information. 2017. [accessed 2022 Mar 29. .
    1. Chang B, Akeda H, Nakamura Y, Hamabata H, Ameku K, Toma T, Miyagi M, Ohnishi M. Impact of thirteen-valent pneumococcal conjugate vaccine on nasopharyngeal carriage in healthy children under 24 months in Okinawa, Japan. J Infect Chemother. 2020;26:465–70. doi:10.1016/j.jiac.2019.12.009.
    1. Japan Pediatric Society . Changes in the immunization schedule recommended by the Japan Pediatric Society; 2020. [accessed 2022 Oct 7]. .
    1. Hu T, Giroux V, Goyette A, Weiss T, Petigara T, Owusu-Edusei K. Health and economic burden associated with 15-valent pneumococcal conjugate vaccine serotypes in children in Canada. ISPPD. Virtual; 2020.
    1. Balsells E, Dagan R, Yildirim I, Gounder PP, Steens A, Munoz-Almagro C, Mameli C, Kandasamy R, Givon Lavi N, Daprai L, et al. The relative invasive disease potential of Streptococcus pneumoniae among children after PCV introduction: a systematic review and meta-analysis. J Infect. 2018;77:368–78. 10.1016/j.jinf.2018.06.004.
    1. Adam HJ, Golden AR, Karlowsky JA, Baxter MR, Nichol KA, Martin I, Demczuk W, Mulvey MR, Gilmour MW, Hoban DJ, et al. Analysis of multidrug resistance in the predominant Streptococcus pneumoniae serotypes in Canada: the SAVE study, 2011–15. J Antimicrob Chemother. 2018;73:vii12–9. doi:10.1093/jac/dky158.
    1. Golden AR, Adam HJ, Zhanel GG. Canadian antimicrobial resistance alliance. Invasive Streptococcus pneumoniae in Canada, 2011-2014: characterization of new candidate 15-valent pneumococcal conjugate vaccine serotypes 22F and 33F. Vaccine. 2016;34:2527–30. doi:10.1016/j.vaccine.2016.03.058.
    1. Suga S, Chang B, Asada K, Akeda H, Nishi J, Okada K, Wakiguchi H, Maeda A, Oda M, Ishiwada N, et al. Nationwide population-based surveillance of invasive pneumococcal disease in Japanese children: effects of the seven-valent pneumococcal conjugate vaccine. Vaccine. 2015;33:6054–60. doi:10.1016/j.vaccine.2015.07.069.
    1. National Institute for Infectious Diseases . Pneumococcal infections in 2017, Japan. Infect Agents Surveill Rep (IASR). 2018;39:107–08.
    1. Epidemiological information on invasive pneumococcal infections in children and adults research group. Epidemiological situation in 2021; 2021. [accessed 2022 Sep 2]. .
    1. European Medicines Agency . Vaxneuvance: ePAR - Product Information; 2022. [accessed 2022 Jan 17]. .
    1. Health Canada . VAXNEUVANCE® Product monograph; 2022. [accessed 2022 Aug 26]. .
    1. Food and Drug Administration . VAXNEUVANCE; 2022. [accessed 2022 Aug 30]. .
    1. European Medicines Agency . Prevenar 13 summary of product characteristics; 2021. [accessed 2022 Apr 26].
    1. Bili A, Dobson S, Quinones J, Phongsamart W, Oberdorfer P, Kosalaraksa P, Dagan R, Wilck MB, Vallejos W, Nunn C, et al. 1184. A Phase 3, multicenter, randomized, double-blind study to evaluate the interchangeability of V114 and Prevnar 13™ with respect to safety, tolerability, and immunogenicity in healthy infants (PNEU-DIRECTION). Open Forum Infect Dis. 2021;8:S684. doi:10.1093/ofid/ofab466.1376.
    1. Lupinacci RR, Wittawatmongkol O., Jones J., Quinones J., Ulukol B., Dagan R., Richmond P., Stek J E., Romero L., Koseoglu S., Tamms G., McFetridge R., Li J., Cheon K., Musey L., Banniettis N., Bickham K.. A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED). Vaccine (Online ahead of print). 2023. doi:10.1016/j.vaccine.2022.12.054.
    1. Kobayashi M, Farrar JL, Gierke R, Leidner AJ, Campos-Outcalt D, Morgan RL, Long SS, Poehling KA, Cohen AL, Group APVW, et al. Use of 15-valent pneumococcal conjugate vaccine among U.S. children: updated recommendations of the advisory committee on immunization practices—United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71:1174–81. doi:10.15585/mmwr.mm7137a3.
    1. Saitoh A, Okabe M. Current issues with the immunization program in Japan: can we fill the “vaccine gap”? Vaccine. 2012;30: 4752–56. doi:10.1016/j.vaccine.2012.04.026.
    1. Merck & Co., Inc., Rahway, NJ, USA . Study to evaluate the safety, tolerability, and immunogenicity of V114 in healthy Japanese infants (V114-033) [accessed Nov 12].
    1. Carlsson RM, Claesson BA, Kayhty H, Selstam U, Iwarson S. Studies on a Hib-tetanus toxoid conjugate vaccine: effects of co-administered tetanus toxoid vaccine, of administration route and of combined administration with an inactivated polio vaccine. Vaccine. 1999;18: 468–78. doi:10.1016/S0264-410X(99)00238-8.
    1. Mark A, Carlsson RM, Granstrom M. Subcutaneous versus intramuscular injection for booster DT vaccination of adolescents. Vaccine. 1999;17: 2067–72. doi:10.1016/S0264-410X(98)00410-1.
    1. Food and Drug Administration . VAXNEUVANCE™ (Pneumococcal 15-valent conjugate vaccine) prescribing information; 2021. [accessed Aug 10]. .
    1. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med. 1985;4:213–26. doi:10.1002/sim.4780040211.
    1. Nolan KM, Zhang Y, Antonello JM, Howlett AH, Bonhomme CJ, Greway R, Green T, de Gorguette d’Argoeuves P, Goldblatt D, Murphy RD. Enhanced antipneumococcal antibody electrochemiluminescence assay: validation and bridging to the WHO reference ELISA. Bioanalysis. 2020;12:1363–75. doi:10.4155/bio-2020-0023.
    1. Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika. 1934;26: 404–13. doi:10.1093/biomet/26.4.404.
    1. Kashiwagi Y, Maeda M, Kawashima H, Nakayama T. Inflammatory responses following intramuscular and subcutaneous immunization with aluminum-adjuvanted or non-adjuvanted vaccines. Vaccine. 2014;32:3393–401. doi:10.1016/j.vaccine.2014.04.018.
    1. Cook IF. Subcutaneous vaccine administration – an outmoded practice. Hum Vaccin Immunother. 2021;17: 1329–41. doi:10.1080/21645515.2020.1814094.
    1. Japan Pediatric Society . Request for the creation of guidelines for vaccination methods. Welfare Science Council Immunization and Vaccine Subcommittee; 2014. .
    1. Iwata S, Takata M, Morozumi M, Miyairi I, Matsubara K, Ubukata K, Pneumococcal Meningitis Surveillance Study Group . Drastic reduction in pneumococcal meningitis in children owing to the introduction of pneumococcal conjugate vaccines: longitudinal analysis from 2002 to 2016 in Japan. J Infect Chemother. 2021;27:604–12. doi:10.1016/j.jiac.2020.11.019.
    1. Shinjoh M, Yamaguchi Y, Iwata S. Pediatric bacterial meningitis in Japan, 2013-2015 - 3-5 years after the wide use of Haemophilus influenzae type b and Streptococcus pneumoniae conjugated vaccines. J Infect Chemother. 2017;23:427–38. doi:10.1016/j.jiac.2017.02.014.
    1. Platt HL, Greenberg D, Tapiero B, Clifford RA, Klein NP, Hurley DC, Shekar T, Li J, Hurtado K, Su SC, et al. A phase II trial of safety, tolerability and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in healthy infants. Pediatr Infect Dis J. 2020;39:763–70. doi:10.1097/INF.0000000000002765.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する